DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry Clinics

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire DIAGNOS Accelerates Nationwide Deployment of Its CARA System Solution Licensed by Health Canada Following the Successful Installation of a First Group of Optometry ClinicsAuthor of the article:BROSSARD, Quebec, Oct. 20, 2026 (GLOBE NEWSWIRE) — Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce the successful initial deployment of its newly licensed CARA System software platform (CARA) across its Canadian network.THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountFollowing receipt of Health Canada medical device marketing authorization, DIAGNOS rapidly initiated installation of optometry clinics onto the CARA. The Corporation is pleased to report that the first phase of deployment has been successfully executed, validating its onboarding capacity and efficiency.This advertisement has not loaded yet, but your article continues below.DIAGNOS has set up 28 stores in two weeks to support continued expansion across Canada, bringing to more than 60 optometrists now utilizing CARA.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againInitial real-world operations have yielded excellent feedback from end-users. Optometrists highlight the system’s intuitive interface, the precision of its AI-assisted retinal image analysis as well as the processing speed of CARA. Furthermore, participating clinics have reported positive patient feedback, driven by the speed and efficiency of the AI-enhanced assessments.“The feedback we are receiving from optometrists and clinic staff validates our core mission: delivering a technology that not only meets regulatory standards but supports clinicians in providing better, faster care. With these successful early deployments, we are now fully determined to pursue our rollout strategy to equip clinics across all Canadian provinces,” said André Larente, President and Chief Executive Officer of DIAGNOSAbout DIAGNOSDIAGNOS is a public Canadian corporation dedicated to the early detection of critical eye-related health problems. DIAGNOS manufactures CARA System, a software platform which assists health specialists in the detection of retinal eye pathologies. By developing innovative products based on AI technologies, DIAGNOS’ solutions provide healthcare clinicians with valuable information that refines diagnostic accuracy, streamlines workflows, and improves patient outcomes. CARA System is currently licensed for commercialization in Canada and Saudi Arabia.This advertisement has not loaded yet, but your article continues below.Additional information is available at www.diagnos.com and www.sedarplus.com.This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.caThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.